SPY330.65-3.85 -1.15%
DIA276.52-2.38 -0.85%
IXIC10,793.28-117.00 -1.07%

Oppenheimer Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $162

Oppenheimer maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and raises the price target from $140 to $162.

Benzinga · 05/07/2020 14:14

Oppenheimer maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and raises the price target from $140 to $162.